Summary
The neuroendocrinological effects of acute oral administration of 20 mg zetidoline, a new antipsychotic drug with antidopaminergic properties, were evaluated in 8 healthy volunteers, by a double-blind, crossover comparison with placebo. Zetidoline significantly increased serum prolactin (p<0.01 at 1–3 h; p<0.05 at 4–6 h). No significant change was observed in blood levels of aldosterone, renin, cortisol, growth hormone and electrolytes, or in blood pressure and heart rate. The data suggest that the drug increases prolactin through blockade of dopaminergic receptors. The lack of change in the aldosterone levels may be evidence against the hypothesis of dopaminergic control of aldosterone secretion.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Fontanella L, Corsico N, Diena A, Galliani G, Glässer A (1981) Synthesis of new psychotropic 2-imidazolidinones. Farmaco 36: 3–12
Barone D, Corsico N, Diena A, Restelli A, Glässer A, Rodenghi F (1982) Biochemical and pharmacological activities of zetidoline (DL 308-IT): a new antidopaminergic agent. J Pharm Pharmacol 34: 129–132
Weiner RI, Ganong WF (1978) The role of brain monoamines and histamine in the regulation of anterior pituitary secretion. Physiol Rev 58: 905–976
Campbell DJ, Mendelsohn FAO, Adam WR, Funder JW (1981) Is aldosterone secretion under dopaminergic control? Circ Res 49: 1217–1227
Barbieri C, Ferrari C, Caldara R, Testori GP, Dal Bo GA, Bertazzoni A (1980) Clonidine-induced hyperglycemia: evidence against a growth hormone-mediated effect. J Pharmacol Exp Ther 214: 433–436
Barbieri C, Caldara R, Ferrari C, Crossignani RM, Recchia M (1981) Inhibition of the renin-angiotensin-aldosterone system by L-dopa with and without inhibition of extracerebral dopa decarboxylase in man. Clin Sci 61: 187–190
Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96
Frantz AG (1978) Prolactin. N Engl J Med 298: 201–207
Sowers JR, Golub M, Tuck M, Sowers DK (1981) Role of prolactin and the renin-angiotensin system in mediating dopaminergic control of aldosterone secretion in the rat. Clin Exp Hypertension 3: 1–14
Robertson D, Michelakis AM (1975) The effect of chlorpromazine on plasma renin activity and aldosterone in man. J Clin Endocrinol Metab 41: 1166–1168
Norbiato G, Bevilacqua M, Raggi U, Micossi P, Moroni C (1977) Metoclopramide increases plasma aldosterone in man. J Clin Endocrinol Metab 48: 37–42
Costa G, Frisina N, De Pasquale R (1980) Increased aldosterone secretion induced by sulpiride. Clin Endocrinol 13: 1–7
Sowers JR, Sharp B, McCallum RW (1982) Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropine, prolactin, renin, aldosterone, and 18-hydroxy-corticosterone secretion in man. J Clin Endocrinol Metab 54: 869–871
Szabadi E, Gaszner P, Bradshaw CM (1981) An investigation of the alpha-adrenoceptor blocking properties of neuroleptics in the human iris “in vivo”. Br J Clin Pharmacol 11: 416P-417P
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barbieri, C., Parodi, M., Bruno, S. et al. Effects of acute administration of zetidoline, a new antidopaminergic drug, on plasma prolactin and aldosterone levels in man. Eur J Clin Pharmacol 26, 29–32 (1984). https://doi.org/10.1007/BF00546704
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00546704